Nivolumab-induced folliculitis: A case of immune-related cutaneous adverse reaction
{{output}}
Nivolumab, a human IgG4 PD-1 immune checkpoint inhibitor antibody, blocks PD-1 and can restore anticancer immune responses by impairing T-cell suppression via the PD-1 pathway. Nivolumab is generally well-tolerated, with fewer treatment-related adverse events ... ...
